Skip Navigation

Allen Dale Everett, M.D.

Allen Dale Everett, M.D.

Headshot of Allen Dale Everett
  • Director of the Pediatric Proteome Center
  • Professor of Pediatrics
Male

Expertise

Cardiology, Pediatric Cardiology, Pediatric Congenital Heart Disease ...read more

Research Interests

Biomarkers of Pulmonary Hypertension and Brain Injury; Proteomics; Metabolomics; Environmental Exposure from Medical Plastics ...read more

Request an Appointment

Insurance Information

Main Phone

443-997-5437

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 443-997-5437
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, Pediatric Cardiology, M2201
Baltimore, MD 21287 map

Johns Hopkins Community Physicians - Hagerstown

Appointment Phone: 443-997-5437
12916 Conamar Drive
Suite 204
Hagerstown, MD 21742 map

Johns Hopkins Health Care and Surgery Center

Appointment Phone: 443-997-5437
6420 Rockledge Drive
Johns Hopkins Children's Center Specialists, Suite 2300
Bethesda, MD 20817 map

Background

Dr. Allen Everett is a professor of pediatrics at the Johns Hopkins University School of Medicine. His areas of clinical expertise include general pediatric cardiology. 

Dr. Everett earned his M.D. from East Tennessee State University. He completed his residency in pediatrics and fellowship in pediatric cardiology at the University of Virginia. Dr. Everett joined the Johns Hopkins faculty in 2003.

He has become the program leader at Johns Hopkins in pediatric biomarker discovery, with a particular focus on brain injury, pulmonary hypertension and effects of medical plastics exposure on congenital heart disease outcomes.  He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies. Dr. Everett also serves as the director of the Pediatric Proteome Center.

Dr. Everett is an author of over 140 peer review papers, three book chapters, editor/author of the Illustrated Field Guide to Congenital Heart Disease and Repair, now in its fourth edition, and senior associate editor for the journal, Cardiology in the Young. He is a co-developer of PedCathTM cardiac catheterization software with Scientific Software Solutions which has been translated into five languages, has five US biomarker patents filed and brain injury biomarkers licensed to ImmunArray, Ltd.

...read more

Titles

  • Director of the Pediatric Proteome Center
  • Professor of Pediatrics

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; East Tennessee State University (1984)

Residencies

  • Pediatrics; University of Virginia School of Medicine (1987)

Fellowships

  • Pediatric Cardiology; University of Virginia School of Medicine (1991)

Board Certifications

  • American Board of Pediatrics (Pediatric Cardiology) (1991)

Research & Publications

Research Summary

Dr. Everett has become the program leader at Johns Hopkins in pediatric biomarker discovery, with a focus on neonatal brain injury and pulmonary hypertension. This includes both protein and metabolic indicators of diagnosis and outcomes.  

He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies.  Active studies as PI include: NICHD R01 HD086058, "Adult Biomarkers in Neonatal Brain Injury and Development", NHLBI R01HL150070, "Role of IGF axis in pulmonary hypertension" and Children's Heart Foundation "Role of cyclohexanone toxicity in mediating congenital cardiac surgical outcomes". Co-investigator on NINDS R01 NS106292 "Biomarkers of Brain Injury in Critically-Ill Children on Extracorporeal Membrane Oxygenation (ECMO)", NINDS 1 U01 NS114144 "Blood test to aid treatment decisions for perinatal asphyxiation", NICHD 1R01HD100540 "Renal Anhydramnios Fetal Therapy (RAFT) Trial", NHLBI "The Hemodynamic and Metabolic Effects of Advanced Circulatory Support for Resuscitation" and NHLBI "IKDR-PREVAIL".

Technology Expertise Keywords

Proteomics; biomarkers; assay development; metabolomics

Selected Publications

View all on PubMed

Griffiths M, Yang J, Simpson CE, Vaidya D, Nies M, Brandal S, Damico R, Ivy D, Austin ED, Pauciulo MW, Lutz KA, Rosenzweig EB, Hirsch R, Yung D, Nichols WC, Everett AD. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest. 2021 Feb 18:S0012-3692(21)00284-1. doi: 10.1016/j.chest.2021.01.085. Online ahead of print.

Yang J, Griffiths M, Nies MK, Brandal S, Damico R, Vaidya D, Tao X, Simpson CE, Kolb TM, Mathai SC, Pauciulo MW, Nichols WC, Ivy DD, Austin ED, Hassoun PM, Everett AD. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Med. 2020 Oct 6;18(1):268.

Griffiths M, Yang J, Nies M, Vaidya D, Brandal S, Williams M, Matsui EC, Grant T, Damico R, Ivy D, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD.Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatr Res. 2020 Dec;88(6):850-856.

Dietrick B, Molloy E, Massaro AN, Strickland T, Zhu J, Slevin M, Donoghue V, Sweetman D, Kelly L, O'Dea M, McGowan M, Vezina G, Glass P, Vaidya D, Brooks S, Northington F, Everett AD. Plasma and CSF Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes. J Pediatr. 2020 Jun 28:S0022-3476(20)30832-5.

Chen JY, Griffiths M, Yang J, Nies MK, Damico RL, Simpson CE, Vaidya RD, Brandal S, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. J Pediatr. 2020 Aug;223:164-169.

Patents

A Multi-protein Biomarker Assay for Brain Injury Detection and Outcome
Patent # WO2015009907 A1 | 01/22/2015

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

Biosensor Systems and Related Methods for Detecting Analytes in Aqueous and Biological Environments
Patent # US20140349005 A1 | 11/27/2014

Disclosed herein are biosensor systems and related methods for detecting analytes in aqueous and biologic environments. A biosensor system for detecting binding of an analyte of interest may include a detector configured to detect a change in an electrical property on a surface thereof. The detector may be a FET. The system also may include a passive layer disposed on a top surface of the detector. Further, the system may include a hydrophobic layer disposed on the passive layer. The system also may include a receptor-attachment material configured for binding to an analyte. A receptor may bind to the analyte, and the receptor may be attached to the receptor-attachment material. The binding of the analyte to the receptor can cause the change of the electrical property at the surface. In response to the change for example, a current may change for indicating the binding of the analyte to the receptor.

Assay Reagents for a Neurogranin Diagnostic Kit
Patent # US20140141458 A1 | 05/22/2014

The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

Assay Reagents for a Neurogranin Diagnostic Kit
Patent # EP2707389 A2 | 03/19/2014

The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

Biomarkers of Pulmonary Hypertension
Patent # WO2013090811 A1 | 06/20/2013

Methods are disclosed for predicting or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers.

Activities & Honors

Professional Activities

  • Senior Associate editor, Cardiology in the Young
  • Co-developer, PedCathTM cardiac catheterization software, Scientific Software Solutions

Videos & Media

Recent News Articles and Media Coverage

Chemicals in IV Tubing May Hinder Babies' Brain Development, MedPage Today May 6, 2020

Is this you? Edit Profile
back to top button